A Study of Mosliciguat in PH-ILD (PHocus) (Phocus)

Recruitment & Eligibility

Inclusion Criteria

Participants willing and able to provide informed consent.
Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include: a.Idiopathic interstitial pneumonia (IIP). b.Chronic hypersensitivity pneumonitis. c.ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) -<70% of predicted.
Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).
Ability to perform 6MWD >= 100 meters. Note: Other inclusion criteria may apply.

Exclusion Criteria

Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
Exacerbation of underlying lung disease within 28 days prior to randomization.
Initiation of pulmonary rehabilitation within 28 days prior to randomization.
Receiving ->10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.
Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization. Note: Other exclusion criteria may apply.

Study & Design

Primary Outcome Measures

Name	Time	Method
Percent change from baseline in PVR	Week 16	Assessed at estimated peak exposure at Week 16 by right heart catheterization (RHC)

Secondary Outcome Measures

Name	Time	Method
Change in 6MWD from baseline	Week 16	measured at estimated peak exposure at Week 16 using the 6-Minute Walk Test (6MWT)

Recruitment & Eligibility